Forest Takes Option On Trevena’s Heart Failure Drug, And Some Equity
This article was originally published in The Pink Sheet Daily
Executive Summary
Already strong in both CNS and cardiovascular drugs, Forest obtained an option to license the Pennsylvania start-up’s lead program in acute heart failure. In the process, Forest took a stake in Trevena as the young company shifts its focus toward pain drugs based on Nobel Prize-winning research.